Author: Xu, Yingying; Yuen, Pak-Wai; Lam, Jenny Ka-Wing
Title: Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives Document date: 2014_7_10
ID: 0bma2749_52
Snippet: Although PEI appeared as a promising vector for gene delivery including DNA vaccines, the cationic PEI is highly charged and non-biodegradable, and it often encounters toxicity problems which cannot be ignored. In this regard, many groups are developing low toxic or biodegradable PEI derivatives for gene delivery application. Mann et al. has developed a PEI derivative, deacylated PEI (dPEI), as DNA vaccine delivery agent [149] . dPEI is a nearly .....
Document: Although PEI appeared as a promising vector for gene delivery including DNA vaccines, the cationic PEI is highly charged and non-biodegradable, and it often encounters toxicity problems which cannot be ignored. In this regard, many groups are developing low toxic or biodegradable PEI derivatives for gene delivery application. Mann et al. has developed a PEI derivative, deacylated PEI (dPEI), as DNA vaccine delivery agent [149] . dPEI is a nearly fully hydrolysed linear PEI with 11% additional free protonatable nitrogen atoms, enabling more efficient binding with DNA, reduced toxicity and high transfection efficiency. It is an effective DNA vaccine carrier for pulmonary delivery to elicit both systemic and mucosal immune responses, and offers protection against influenza challenge in vaccinated mice. This system has a potential to be exploited for intranasal administration. (PEI) (a,b) , Chitosan (c) and Poly(lactic-co-glycolic acid) (PLGA) (d).
Search related documents:
Co phrase search for related documents- co glycolic acid and dna vaccine carrier: 1
- co glycolic acid and gene delivery: 1
- co glycolic acid and high transfection: 1
- co glycolic acid and immune response: 1, 2, 3, 4, 5, 6, 7, 8
- co glycolic acid and intranasal administration: 1
- co glycolic acid and pulmonary delivery: 1, 2
- co glycolic acid and reduce toxicity: 1
- delivery agent and dna vaccine: 1
- delivery agent and intranasal administration: 1
- delivery agent and pulmonary delivery: 1, 2, 3
- delivery agent and reduce toxicity: 1
- dna vaccine and efficient binding: 1
- dna vaccine and gene delivery: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- dna vaccine and high transfection: 1
- dna vaccine and high transfection efficiency: 1
- dna vaccine and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- dna vaccine and influenza challenge: 1, 2, 3, 4, 5
- dna vaccine and intranasal administration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- dna vaccine and mucosal systemic immune response: 1
Co phrase search for related documents, hyperlinks ordered by date